Mylan Inc has issued a clarification to the stock exchanges regarding its recent disposal of equity shares in Biocon Limited , correcting a typographical error in a previous filing. The US-based pharmaceutical company confirmed that its post-disposal holding in the Indian biopharmaceutical firm is nil, rectifying an inadvertent disclosure that had incorrectly stated a remaining stake.

The correction relates to a disclosure made on July 15, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. In that initial filing, Mylan reported selling 9,19,67,019 equity shares, representing 5.64% of Biocon's total voting capital, on July 14, 2026. However, the document erroneously listed the seller's post-disposal holding as 9,19,67,019 shares (5.64%), rather than zero.

Transaction Details

The clarified filing confirms that Mylan completely exited its stake in Biocon through an open market sale. The transaction involved the entire block of shares held by the seller prior to the disposal. There were no encumbrances, pledges, or convertible securities associated with the sold shares.

Regulatory Compliance

Mylan submitted the clarificatory disclosure to both the National Stock Exchange of India Ltd and BSE Limited on August 26, 2026. The company stated that all other information in the original July 15 disclosure remains unchanged. The correction was signed by Suresh Krishnamachari, Assistant Treasurer for Global Treasury Operations at Mylan Inc.

Biocon's total voting capital remains unchanged at INR 8,14,84,70,675, divided into 1,62,96,94,135 equity shares with a face value of INR 5 each. The total diluted share capital stands at INR 8,15,82,64,600.

Biocon has received marketing approval for its pegfilgrastim biosimilar from Japan’s Ministry of Health, Labour and Welfare (MHLW). The approval, confirmed on August 25, 2026, strengthens the company’s biosimilar portfolio in one of Asia’s largest pharmaceutical markets.

Biocon Biologics Ltd., a wholly-owned subsidiary of Biocon, developed and manufactured the product. It serves as a biosimilar to Neulasta®, a registered trademark of Amgen Inc. Global Regulatory Partners Japan acts as the Marketing Authorization Holder on behalf of Biocon.

Commercialisation Strategy

Sandoz K.K. will exclusively promote, sell, and distribute the pegfilgrastim biosimilar in Japan. This partnership model allows Biocon to leverage local distribution networks while focusing on manufacturing and regulatory compliance.

The company stated that this approval reaffirms its commitment to increasing patient access to high-quality and affordable medications globally. The move adds to Biocon’s existing footprint in the Japanese biosimilar sector.

What the Numbers Show

The approval marks a strategic expansion into a regulated high-income market. By securing exclusive distribution rights with Sandoz K.K., Biocon mitigates direct commercial execution risk in Japan while capturing revenue through supply agreements. This structure contrasts with fully integrated launch models, potentially improving margin predictability for this specific asset.